FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (PFS).

Trial Details

NCT ID
NCT06733038
Phase
PHASE3
Sponsor
Gruppo Oncologico del Nord-Ovest
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Atezolizumab
  • Bevacizumab
  • Irinotecan (CPT-11)
  • Oxaliplatin
  • Leucovorin
  • Fluorouracil (5-FU)
Locations (sample)
  • Brescia, BS, Italy|45.53558,10.21472
  • Catania, CT, Italy|37.49223,15.07041
  • Meldola, FC, Italy|44.12775,12.0626
  • San Giovanni Rotondo, FG, Italy|41.70643,15.7277
  • Florence, FI, Italy|43.77925,11.24626

Key Eligibility Criteria

  • Histologically proven diagnosis of colorectal cancer;
  • Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease;
  • Proficient mismatch repair (pMMR) status in tumour tissue (primary or metastatic), as determined by a local laboratory assay in a CLIA- or similarl…
  • Immunoscore IC-high status in tumour tissue (primary or metastatic), as determined by a sponsor-defined central laboratory (HEGP, AP-HP, INSERM, Fr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →